HELIESS 2 aud 1977 HELIESS 2 aud	ME	RCK	(& (. N	YSE-mr	K		R	ecent Rice	56.34	4 P/E RATI	o 13 .	9 (Traili Medi	ng: 14.5) an: 12.0)	RELATIV P/E RATI	e 0.6	8 DIV'D YLD	3.4	%	/ALUI LINE	Ξ			
EFTV Instant (ST) Line degrees Instant (ST) Line degrees Instant (ST) Line degrees Instant (ST) Line degrees Line degrees <thline degrees<="" th=""> Line degrees</thline>	TIMELIN	IESS 2	2 Raised	12/29/17				61.2 22.8	38.4 20.0		37.9 29.5													
Dit Dit <thdit< th=""> <thdit< th=""> <thdit< th=""></thdit<></thdit<></thdit<>	SAFET				I FGFI	NDS		· .												2020	2021			
Th. B. (10): Alley: Description: Description: <thdescription:< th=""> <thdescription:< th=""> <thdescripti< td=""><td>TECHNI</td><td>CAL 4</td><td>4 Lowere</td><td>d 12/29/17</td><td>Options:</td><td>elative Pric</td><td>e Strength</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></thdescripti<></thdescription:<></thdescription:<>	TECHNI	CAL 4	4 Lowere	d 12/29/17	Options:	elative Pric	e Strength																	
Pipe Gail Description Pipe Gail Description Pipe Gail				<u></u>			ates reces	sion														-80		
arr brance brance <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>السار</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>hund.</td> <td>^{իսու}կը։</td> <td>աստերը</td> <td>ן ידידידיין (</td> <td>•</td> <td></td> <td></td> <td></td> <td></td>							السار							hund.	^{իսու} կը։	աստերը	ן ידידידיין (•						
Line Decisions Line De									\bigtriangledown			րող	1111111	-	10							40		
No. 1 No. 0 No. 0 <th< td=""><td>Low</td><td>70 (</td><td>+25%)</td><td>9%</td><td></td><td>•••••</td><td></td><td></td><td></td><td></td><td><u>ur uhti</u></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Low	70 (+25%)	9%		•••••					<u>ur uhti</u>													
Bit Disk	Inside			ASO				* ••1		·····.		• • • • • • • • •			•							- 24		
ml - - - - Not Return to the second secon	to Buy	0 0 0	0 0 0	0 0 0								-					•**••••• *•							
North North <th< td=""><td>to Sell</td><td>7 0 0</td><td>100</td><td>0 0 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>% TO</td><td>T. RETUR</td><td>N 11/17</td><td>-12</td></th<>	to Sell	7 0 0	100	0 0 0															% TO	T. RETUR	N 11/17	-12		
Oto Doi: Doi: <thdoi:< th=""> <thdoi:< th=""> <thdoi:< th=""> Do:</thdoi:<></thdoi:<></thdoi:<>	Institu								har											THIS V STOCK				
Oto Doi: Doi: <thdoi:< th=""> <thdoi:< th=""> <thdoi:< th=""> Do:</thdoi:<></thdoi:<></thdoi:<>	to Buy	856	860	847	shares	12 -				III	յի հա		يا ال		11							F		
Oto Doi: Doi: <thdoi:< th=""> <thdoi:< th=""> <thdoi:< th=""> Do:</thdoi:<></thdoi:<></thdoi:<>		2190042	2183478	32181451															5 yr.	46.9	96.6	<u> </u>		
3185 326	2001						2007	2008	2009	2010						-					UB. LLC			
314 314 314 22 221 252 124 344 346 336 378 334 346 349 349 349 349 349 349 349 349 349 349 349 349 349 344 348 142 Enrings prish 4 54 56 35 46 46 59 35 35 65 35 46 46 59 35 35 65 35 46 46 59 35 55 55 55 36 40 138 130 131 131 131 131 131 134 131 134 131 134 135 136 46 131 134 135 136 136 131 134 135 136 136 131 134 135 135 136 136 131 136 136 136 131 136 136 136 136 136 136 136 136 136 136 136 136 136 136 13	20.99									1			1		1						- 6	17.65		
137 144 145 146 152 1										1			1							•				
7.06 11 7.01 7.88 8.27 8.90 19.00 17.82 17.24 17.00 17.44 16.06 14.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 15.88 16.00 16.88 16.00 16.88 16.00 16.88 16.00<						1	-			-		1		1	1							2.04		
2727 2286 2281 <th< td=""><td>1.20</td><td>1.06</td><td>.86</td><td>.78</td><td>.64</td><td>.45</td><td>.47</td><td>.62</td><td>.47</td><td>.54</td><td>.57</td><td>.65</td><td>.53</td><td>.46</td><td>.46</td><td>.59</td><td>.55</td><td>.55</td><td>Cap'l S</td><td>pending p</td><td>er sh</td><td>.60</td></th<>	1.20	1.06	.86	.78	.64	.45	.47	.62	.47	.54	.57	.65	.53	.46	.46	.59	.55	.55	Cap'l S	pending p	er sh	.60		
227 173 162 162 121 102 91 105 91 108 133 164 168 162 167 Mag Amri PE Raio 15 19% 22% 27% 35% 50% 40% 30% 41% 51% 42% 44% 41% 37% 31% 32% 32% 30% Agg Amri PE Raio 15 110 Det 52763 50% 40% 30% 41% 53% 32% 32% 30% 400% 42% 44% 41% 33% 34% 48% 30% 400% 20% 20% 30% 40% 42% 44% 41% 31% 32% 32% 30% 40% 20% 20% 20% 40% 20%																				· ·		13.35		
11.6	2272.7												-					2670.0						
19% 2.9% 2.7% 3.0% 4.1% 3.1% 4.2% 4.4% 4.1% 3.1% 2.2% 3.0% Jage And Div's Yiel 2.7% PHIL STRCUTURE set of STOPS mill. Due in 5 Yes 5000 mill. Company State and										1			1						-			.95		
Nate 0.55: 22:083 mil. 13:45: 22:55: 22:45: 22:45: 22:55: 12:05: 22:45: 22:55: 12:05: 22:45: 22:55: 12:05: 22:45: 22:55: 12:05: 12:05: 10:05: 10:05:	1.9%					1	1						1		1	1						2.7%		
Name Adds Adds <th< td=""><td>CAPITA</td><td>L STRU</td><td>CTURE</td><td>as of 9/30</td><td>)/17</td><td></td><td>24198</td><td>23850</td><td>27428</td><td>45987</td><td>48047</td><td>47267</td><td>44033</td><td>42237</td><td>39498</td><td>39807</td><td>40200</td><td>41000</td><td>Sales (\$</td><td>mill)</td><td></td><td>45000</td></th<>	CAPITA	L STRU	CTURE	as of 9/30)/17		24198	23850	27428	45987	48047	47267	44033	42237	39498	39807	40200	41000	Sales (\$	mill)		45000		
$ \begin{array}{c} 1000 & 1$								48.5%		1			1		1							36.0%		
Baselson Assets-12/16 \$17.6 bill. Oblig. 519.2 bill. Basels / 2048 20/17 11/23 10/14	LI Debi	\$21838	s mill.	LI Interes						1			1		1	1				•	II)	3000		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	32/5.4 /808																					12750		
										1			1		1									
Instruct 1486 1878 1506 1/24.438.58 sts. 13000																					nill)	10000		
10103/1/T 1050 1053 1050 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073 1073	3915.8 3943										15525	16254		18699	23929	24274	21000		Long-Te	erm Debt (\$mill)	20000		
ARKET CAP: \$133 billion (Large Cap) 10% 14% 12% 12% 12% 12% 12% 21% 21% 22% <th< td=""><td></td><td></td><td>× 2,7 24,4</td><td>30,033 511</td><td>15.</td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td>-</td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td>34000</td></th<>			× 2,7 24,4	30,033 511	15.				-				-		-							34000		
URREENT POSITION20152016930/17NMF 241% 71% 110% 122% 122% 10% 113% 123% 150% $10\%\%$ 120% 110% 150% 110% 150% 110% 150% 110% 150% $10\%\%$ $10\%\%\%$ 1		T CAD.	¢152 hil	lion /l.org	(Con)					1			1		1									
						9/30/17							-		-							22.0%		
Generation 6484 7018 7701 87671 BUSINESS: Merck & Co., Inc. is a global health care company the induced in the participation of the participating the participation of the participation of the par	(\$MII	_L.)								1		1	1		1	1						41%		
ventory (LIFC)4700486652631 mer515430614277919ournert Assets2976430614279192 mer253320726202 mer1 202017204194671 MUAL RATESPastPastFast1 1 MUAL RATES207194671 MUAL RATESPastFastFast1 1 MUAL RATESPastFastFast1 2 MUAL RATES20%3.5%2 mer2.0%3.5%2 mer2.0%3.6%2 mer2.0%3.6%<	Receiva	ables		6484	7018	7671	BUSIN	ESS: Me	erck & Co	., Inc. is a	global	health ca	re comp	any that	Januvia	(diabete	es) and	Zetia (o	cholester	ol). Acqu	ired Sc	hering-		
urrent Assets 29764 30614 27913 cits Payable 2533 2865 566 5157 ther 14085 13829 11690 1075 5175 10703 10715 10703 1071 1071 1071 1071 1071 1071 1071 1071 1071 1071 1071 1071 1071 10704 10724 <td>Invento Other</td> <td>ry (LIF</td> <td>0)</td> <td></td> <td></td> <td>5263 3790</td> <td>deliver</td> <td>s innovat</td> <td>tive heal</td> <td>h solution</td> <td>s throug</td> <td>gh its pr</td> <td>escriptior</td> <td>medi-</td> <td>Plough,</td> <td>11/09. ⊢</td> <td>las 68,00</td> <td>00 emplo</td> <td>yees. O</td> <td>ff/dirs. ow</td> <td>n less th</td> <td>nan 1%</td>	Invento Other	ry (LIF	0)			5263 3790	deliver	s innovat	tive heal	h solution	s throug	gh its pr	escriptior	medi-	Plough,	11/09. ⊢	las 68,00	00 emplo	yees. O	ff/dirs. ow	n less th	nan 1%		
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c}$	Current Assets 29764 30614 27919 cines, vaccine														of common stock; BlackRock, 6.7%; Vanguard, 6.7%; Capital World Investors, 5.1% (4/17, proxy), Chairman/President/CEO; Kenneth									
ther 14025 13829 11690 Imaces and Healthcare Services. Top-grossing drugs in 2016: 07033. Tel: 908-740-4000. Internet: www.merck.com. NNUAL RATES Past Est d' 14-16 We have raised our 2017 EPS target Rheumatoid arthritis drug <i>Remicade</i> and fragelogies of the drugmaker's third-transploy for the system of the system of the distribution of the system of the distribution. Rheumatoid arthritis drug <i>Remicade</i> and fragelogies of the distribution of the distribution of the distribution of the distribution of the distribution. Alse Flow" 5.5% 3.0% 7.0% 3.0% </td <td colspan="7">ACCIS Fayable 2555 2007 2020</td> <td>sed of fo</td> <td colspan="6"></td> <td colspan="8">Frazier. Inc.: NJ. Addr.: 2000 Galloping Hill Road., Kenilworth, NJ</td>	ACCIS Fayable 2555 2007 2020							sed of fo							Frazier. Inc.: NJ. Addr.: 2000 Galloping Hill Road., Kenilworth, NJ									
NNUAL RATES Past change (per sh)Past Form 10 (ms. 5 (ms. 10 (ms. 5 (ms. 10 (ms. 5 (ms. 10 (ms. 5 (ms. 10 (ms. 	Other			14085	13829	11690	liances	and He	ealthcare	Services	. Top-g	rossing	drugs in	2016:	07033.	Tel.: 908-	740-400	0. Interne	et: www.i	merck.con	n.			
change (parsh) 10 Yrs. 5 Yrs. to 20-22 alse Tow" 5.5% 3.0% 5.0% 3.0% 5.0% ash Flow" 5.5% 3.0% 5.0% 3.0% 5.0% ash Flow" 5.5% 3.0% 5.0% Vidends 2.0% 3.5% 2.0% okt Value 7.0% 2.5% 3.0% the incident reduced sales by roughly \$135 multion due to manufacturing disruptions, but does not anticipate much of an effect the incident reduced sales by roughly \$135 standout immuno-oncology asset <i>Keytruda</i> 014 10264 10934 10557 10482 428 015 9425 9785 10073 10215 39807 107 9434 9930 10325 10511 9600 10700 10600 10700 4000 Cal- EARINGS PER BHARE A Mar.31 Jun.30 Sep.30 Dec.31 Year 014 88 85 90 8.7 145 105 1.05 1.15 1.05 4.25 106 89 93 1.07 89 3.5% 106 48 .99 3.107 89 3.5% 107 444 44 44 44 1.16 108 40 44 4.44 44 1.76 108 40 44 44 44 44 1.76 108 40 107 47 47 .47 .47 .47 101 44 48 101 47 47 .47 .47 .47 101 402 102 bit 48 101 47 47 .47 .47 .47 101 402 102 bit 48 101 40 102 bit 48 101 40 102 bit 48 101 1.11 95 3.95 106 46 46 46 46 107 47 .47 .47 .47 101 402 102 bit 48 101 40 102 bit 48 102 bit 4																								
ales13.5%2.0%3.5%quarter failings caller in a negative impact from the highly-publicized Petyaash Flow5.5%3.0%1.0%5.5%due to generics. We anticipate additionalash Flow7.0%-2.5%-3.0%indicated thatash Martings7.0%-2.5%-3.0%indicated thatash Martings7.0%-2.5%-3.0%indicated thatash Martings10.135.000.06.31Fullash Martings10.1310.5710.48242237ash Martings10.1310.5710.48242237ash Martings10.1310.5710.48242237astandoutimmuno-oncology assetkeytruda.Withasset10.1110.4020010001000ash Els9001010010001000ash Els9.9310.0210.11ash Set9.9310.0710.14ash Set9.9310.11.95ash Set9.9310.0710.10ash Set9.9310.11.95ash Set9.9310.2110.11ash Martings10.11.95ash Martings10.11.95ash Martings10.11.95ash Martings10.11.95ash Martings10.11.95ash Martings10.11.95ash Martings10.11.95ash Martings10.11.95ash Martings10.11 <td></td>																								
amings3.5%1.0%5.5%Vidends2.0%3.5%2.0%bok Value7.0%-2.5%-3.0%cal-QUARTERLYSALES (\$mill)FulldarMar.31Jun.30Sep.30Dec.31Vidends93129844109341055710482425978510073102153948859001011539807standout immuno-oncology asset KeytrudaKeytruda.016931298441053610115980010100106001070041000179434993010325105111044Mar.31Jun.30Sep.30Dec.31Vidends8.85.90.87349349onfiset reductions in a few of the com-014.88.90.87349.931.07.89310.951.051.151.06.95.1051.051.11.95.378106.99.931.07101.44.44.4411.95.376116.95.105117.105.420118Mar.31Jun.30119.95.105119.95.105110.95111.95111.95115.95116.95117.05118.95119.95	Sales		3.	5% 2.	.0%	3.5%																		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Earnings 3.5% 1.0% 5.5% pact fro																							
Cultor of the incident reduced sales by Folging \$135Centered around <i>Reyrruda</i> . With Mar.31 Jun.30 Sep.30 Dec.31The incident reduced sales by Folging forward. On a positive note, Merck's going forward. On a positive note, Merck's standout immuno-oncology asset <i>Keytruda</i> ontinued to exhibit strong momentum (sales +194% year over year), as did Hep-C drug Zepatier (+185%). The animal health business also performed well (+16%), help- ing to offset reductions in a few of the com- pany's older franchises (more below). All total.Several mature drugs in decline, Merck's will be leaning heavily on the new product cycle to offset losses in 2018 and beyond encod the most promising new assets in the industry in <i>Keytruda</i> . The immuno- oncology drug surpassed \$1 billion in an- usales last quarter and now is Merck's second-largest revenue generator (10% of total). Current projections suggest annual sales could top \$8 billion by 2021.Att Mar.31 Jun.30 Sep.30 Dec.31 YearFull YearFull YearMar.41 Mar.31 Jun.30 Sep.30 Dec.31 YearFull YearFull (previously \$39.4 billion-\$40.5 billion sales outlook to \$40.0 billion-\$40.5 billion several core drugs are likely to con- time to face pressure in 2018. The sales -51%), and declines are expected to persist over the next several quarters.Company's Financial Strength A+++) should appeal to risk-averse income-oriented investors mental available.Dilude dearnings (adjusted). Quarters may'13, (\$2.02); '14, 58; '15, (\$2.03); '16, (\$1.74)mentlan available.Company's Financial Strength (pin millions.Company's Financial Strength (pin millions.Atter	Dividends 2.0% 3.5% 2.0% cyberatta							rattac	ack. Management indicated that							The long-term growth story remains								
darMar.31Jun.30Sep.30Dec.31Year0141026410034105571048242237015942597851007310215394980169312984410536101159312984410536101159301032510611402001079434993010325106511402001010010600107001089600101001060010700104888590.873058696933.59106.89931.07.89016.89931.07.89017.881.011.11.9530659.051.55.05108.951.054.20108.811.11.953091.07.89.378016.89.931.07.89107.881.011.11.95308.90.151.05108.951.05.420109.44.44.44.44.441.76.15.45.45.45.16.46.184.16.46.46.16.48.46.16.44.44.17.47.47.47.47.48.44.54.45.51																								
0141026410934105571048242237 39484going forward. On a positive note, Merck's standout immuno-oncology asset <i>Keytruda</i> (all standout immuno-oncology drug surpassed \$1 billion in an unal sales last quarter and now is Merck's second-largest revenue generator (10% of total. Current projections suggest annual sales outlook to \$40.0 billion-\$40.5 billion (previously \$3.76-\$3.88) and its sales outlook to \$40.0 billion-\$40.5 billion (previously \$39.4 billion-\$40.4 billion).cycle to offset losses in 2018 and beyond the most promising new assets in the industry in <i>Keytruda</i> . The immuno- oncology drug surpassed \$1 billion in an nual sales last quarter and now is Merck's second-largest revenue generator (10% of total. Current projections suggest annual sales outlook to \$40.0 billion-\$40.5 billion (previously \$39.4 billion-\$40.4 billion).014.44.44.441.76014.44.44.44.45.45015.45.45016.46.46.184017 <t< td=""><td>endar</td><td colspan="8">Mar 24 Jun 20 Can 20 Dea 24 Mar Internet at</td><td colspan="7"></td><td colspan="8"></td></t<>	endar	Mar 24 Jun 20 Can 20 Dea 24 Mar Internet at																						
01693129844105361011539807017943499301032510511402000189600101001060010700410000189600107004100041000014.88.85.90.87.349014.88.85.90.87.349016.89.93.107.89.378017.86.101.11.95.359016.89.93.105.1.054.20016.93.105.1.054.20017.88.101.1.11.95.359018.95.1.05.1.054.20014.44.44.441.76014.44.44.44014.44.44.44.44.44.44.48.48.76017.48.44.48.76018.48014.44.44.44.44.48.48016.46.48.44.48.76.48.76.78.74.74.74.74.74.75.715.76.74.77.74.78.74.78.74.79.74.76.74.76.75<	2014	10264 10934 10557 10482 42237 going forward.								On a positive note, Merck's					cycle to offset losses in 2018 and beyond.									
0179434993010325105114020001896001010010600107004100012al-EARNINGS PER SHARE AFull business also performed well (+16%), help- ing to offset reductions in a few of the com- pany's older franchises (more below). All told, management upped its full-year ad- justed earnings guidance to \$3.91-\$3.97 a share (previously \$3.76-\$3.88) and its sales outlook to \$40.0 billion-\$40.5 billion (previously \$3.9.4 billion).billion franchises second-largest revenue generator (10% of total). Current projections suggest annual sales could top \$8 billion by 2021.016.89.931.07.89.378 .378017.881.011.11.95.95018.951.151.05.20014.44.44.441.76 time to face pressure in 2018. The sales -51%), and declines are expected to persist over the next several quarters.market in the year ahead. An attractive dividend yield (3.4%) and superior grades for Safety (1) and Financial Strength Michael Ratty018.48.44.44.1.84016.46.46.46017.47.47.47018.48.020; '14, 58¢; '15, (\$2.03); '16, (\$1.74).019Diluted earnings (adjusted). Quarters may sum due to rounding. Excludes nonrecur-'13, (\$2.02); '14, 58¢; '15, (\$2.03); '16, (\$1.74).018.48.44.44019.48'13, (\$2.02); '14, 58¢; '15, (\$2.03); '16, (\$1.74).019.48.44.44019	2015	9425 9785 10073 10215 39498 standout immuno-oncology asset <i>Keytruda</i>											Encouragingly, the drugmaker possesses											
01896001010010600107004100041000Gales F137/8 yearover year), as that hep/Loncology drug surpassed \$1 billion in an- oncology drug surpassed \$1 billion in an- nual sales last quarter and now is Merck's second-largest revenue generator (10% of total). Current projections suggest annual sales could top \$8 billion by 2021.014.88.85.90.873.49015.85.86.96.933.59016.89.931.07.89.97017.881.011.11.95.95018.951.051.151.054.20018.951.051.151.054.20024QUARTERLY DIVIDENDS PAID P* todarFull YearFull Year024.44.44.441.76014.44.44.441.76015.45.45.45016.46.46.184017.47.47018.48.184019.48.184011.48.184012.48.184013.48.48014.48015.45.48.46.48.48016.46.48.48017.47.48.184.48.184.48.184.48.184.49.44.49.48 <td< td=""><td>2010</td><td></td><td colspan="9">0020 10225 10E11 10200 continued to exhibit Strong momentum</td><td></td><td colspan="8">one of the most promising new assets in the industry in <i>Keytruda</i>. The immuno-</td></td<>	2010		0020 10225 10E11 10200 continued to exhibit Strong momentum										one of the most promising new assets in the industry in <i>Keytruda</i> . The immuno-											
Cal- IdarEARNINGS PER SHARE A Mar.31 Jun.30 Sep.30 Dec.31Full Yearbusiness also performed well (+16%), help- ing to offset reductions in a few of the com- pany's older franchises (more below). All told, management upped its full-year ad- justed earnings guidance to \$3.91-\$3.97 a share (previously \$3.76-\$3.88) and its sales outlook to \$40.0 billion-\$40.5 billionnual sales last quarter and now is Merck's second-largest revenue generator (10% of total). Current projections suggest annual sales could top \$8 billion by 2021.016.89.931.07.893.78 3.78 3.783.79 3.783.79 3.78.7151.054.20017.881.011.11.95 4.20.95.95 4.20.95.1051.151.054.20Cal- 014.44.44.441.76 1.80Full YearFull YearFull YearFull YearFull YearFull YearFull YearSeveral core drugs are likely to con- tinue to face pressure in 2018. The sales -51%), and declines are expected to yersist over the next several quarters.The stock's fine time to sale on our system, shares of market in the year ahead. An attractive dividend yield (3.4%) and superior grades for Safety (1) and Financial Strength income-oriented investors Michael Ratty10.48.148.14.14.65.62.03; '14, 58c; '15, (\$2.03); '16, (\$1.74).ment plan available. (C) in millions.Company's Financial Strength Stock's Price StabilityA++	2018	9600	600 10100 10600 10700 41000 drug Zepatie																					
014.88.85.90.873.49015.85.86.96.93.359016.89.93.107.89.378017.881.011.11.95.951.051.151.05018.951.051.151.054.20Cal-QUARTERLY DIVIDENDS PAIDBaFull Year014.44.44.44.441.76015.45.45.45.180016.46.46.46.46017.47.47.47018.48.181016.48.181017.48.181018.48.181016.48.181017.47.47.48.181018.181018.181014.181015.155	Cal-	al- EARNINGS PER SHARE A Full business							also performed well (+16%), help-						nual sales last quarter and now is Merck's									
015 .85 .86 .96 .93 3.59 016 .89 .93 1.07 .89 3.78 016 .89 .93 1.07 .89 3.78 017 .88 1.01 1.11 .95 3.78 018 .95 1.05 1.15 1.05 4.20 value optimum sales outlook to \$40.0 billion-\$40.5 billion sales outlook to \$40.0 billion-\$40.5 billion 014 .44 .44 .44 .44 1.76 .50 1.80 015 .45 .45 .45 1.80 1.84 1.76 .50 016 .46 .46 .46 .46 .46 .46 .46 .46 .46 .46 .48 1.84 .44 .44 .44 .44 .44 .44 .44 .44 .44 .44 .44 .44 .46 .46 .46 .46 .46 .46 .46 .46 .46 .46 .46 .46 .48 .48 .184 .48 <	endar 2014	14 00 05 00 07 040 mg to on													second-largest revenue generator (10% of									
016.89.931.07.893.78017.881.011.11.953.78018.951.051.151.054.20018.951.051.151.054.20014QUARTERLY DIVIDENDS PAIDB-Full year014Mar.31Jun.30Sep.30Dec.31014Mar.31Jun.30Sep.30Dec.31015.45.45.45016.46.46.46017.47.47.48.76018.88017.47.48.76018.89.910.92.92.93.95	2014		.85 .86 .96 .93 3.59 told manager																			nual		
017 .00 1.01 1.00 1.01 1.00 1.01 1.00 1.01 1.00 1.01 1.00 1.01 1.00 1.01 1.01 1.01 <	2016	.89 .93 1.07 .89 3.78 justed ea																						
Sales outlook to \$40.0 billion-\$40.5 billion Based on our system, snares of MRK are for out system, snare for out system, snares of MRK are	2017 2018						shar	e (pr	reviou	sly \$3	3.76-\$	3.88)	and	its	raise	ed a :	notch	ı to 2	2 (Ab	ove A	lvera	ge).		
Indar Mar.31 Jun.30 Sep.30 Dec.31 Year Several core drugs are likely to con- tinue to face pressure in 2018. The Zetia/Vytorin cardiovascular franchise has 016 After the year ahead. An attractive dividend yield (3.4%) and superior grades for Safety (1) and Financial Strength income-oriented investors <i>Zetia/Vytorin</i> cardiovascular franchise has been hit hard since going off patent (Q3 48 Gate the year ahead. An attractive dividend yield (3.4%) and superior grades for Safety (1) and Financial Strength income-oriented investors <i>Michael Ratty</i> Diluted earnings (adjusted). Quarters may sum due to rounding. Excludes nonrecur- Next egs. report due early February. '13, (\$2.02); '14, 58¢; '15, (\$2.03); '16, (\$1.74). Next egs. report due early February. ment plan available. (C) In millions. Company's Financial Strength Stock's Price Stability A++									look to \$40.0 billion-\$40.5 billion						Based on our system, shares of MRK are									
014 .45 .45 .45 .45 .45 .45 .45 .45 .46 .46 .46 .46 .46 .1.84 Leven hit hard since going off patent (Q3 .4++) should appeal to risk-averse sales -51%), and declines are expected to persist over the next several quarters. .4++) should appeal to risk-averse merse mers	(previous														now pegged to outperform the broader									
015 .45 .45 .45 .45 .45 .45 .45 .45 .46 .46 .46 .46 .46 .46 .46 .46 .46 .47 .48 .51%), and declines are expected to persist over the next several quarters. .010 <	bever u																							
016 .46 .46 .46 .46 .46 .46 .46 .46 .46 .46 .47 .	2015	.45	.45	.45	.45	1.80																		
018 .48 Safes -57.67, and decimes are expected to method and the	2016					1.84	been	hit l	hard	since g	going	off p	atent	(Q3	(A++) sh	ould	appe	eal t					
Diluted earnings (adjusted). Quarters may 13, (\$2.02); '14, 58¢; '15, (\$2.03); '16, (\$1.74). ment plan available. Company's Financial Strength Stock's Price Stability A++ sum due to rounding. Excludes nonrecur- Next egs. report due early February. (C) In millions. Stock's Price Stability 95	2017		.47	.47	.47																			
sum due to rounding. Excludes nonrecur- Next egs. report due early February. (C) In millions. Stock's Price Stability 95						L	•						-		wiich	iaei Ra		-			0			
	ot sum	due to	rounding	. Exclude	s nonreci	ur- Nex	t egs. rep	ort due e	early Feb	ruary.		ment pla (C) In mi	n availab Ilions.	le.			Sto	ck's Pric	e Stabil	ity –	h	95		

(C) In millions.
 (Fort deg S. Feport due early February.
 (C) In millions.
 (C) In millions.

Price Growth Persistence55Earnings Predictability100

To subscribe call 1-800-VALUELINE